Securities code: Shanghai Junshi Biosciences Co.Ltd(688180) securities abbreviation: Shanghai Junshi Biosciences Co.Ltd(688180) Announcement No.: pro 2022012 Shanghai Junshi Biosciences Co.Ltd(688180)
Special report on the use of previously raised funds
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
According to the provisions on the report on the use of the previously raised funds (Zheng Jian FA FA Zi [2007] No. 500) issued by the China Securities Regulatory Commission (hereinafter referred to as “CSRC”), Shanghai Junshi Biosciences Co.Ltd(688180) (hereinafter referred to as “the company” or “the company”) will report the use of the previously raised funds as of December 31, 2021 as follows:
1、 Previous fund raising
(I) funds raised by public offering of H shares
With the approval of the reply on approving Shanghai Junshi Biosciences Co.Ltd(688180) issuance of overseas listed foreign shares (zjxk [2018] No. 1914) by the CSRC and the approval of the stock exchange of Hong Kong Limited (hereinafter referred to as “the stock exchange of Hong Kong”), in December 2018, the company publicly issued 158910000 overseas listed foreign shares (H shares) on the stock exchange of Hong Kong, The issue price per share is HK $19.38, and the total amount of raised funds is HK $307967580000 (equivalent to RMB 271319437980). As of December 24, 2018, after deducting the underwriter’s Commission and other issuance expenses of HK $11548274529 (equivalent to RMB 10174029860), the company obtained interest income of HK $27619844 (equivalent to RMB 24333083), and actually received raised funds of HK $296446925315, equivalent to RMB 261169741203.
The funds raised from H-share public offering were remitted to the 020601-1256340-4 special account for raised funds opened by the company in China Merchants Yonglong Bank Co., Ltd. on December 24, 2018, and the initial deposit amount was HK $296446925315 (equivalent to RMB 261169741203). As of December 31, 2021, the balance of 020601-1256340-4 special account for raised funds was HK $16821992 (equivalent to RMB 13753661), and the remaining unused raised funds had been transferred to other bank accounts of the company and relevant subsidiaries of the company.
(II) public offering and over allotment of H shares
On January 4, 2019, according to the over allotment right specified in the H-share prospectus, the company over allotted 23836500 overseas listed foreign shares (H shares), with an issue price of HK $19.38 per share and a total raised capital of HK $46195137000 (equivalent to RMB 40383788765). After deducting the underwriter’s Commission and other issuance expenses of HK $1389411136 (equivalent to RMB 1214623215), the actually received raised funds are HK $44805725864, equivalent to RMB 39169165550.
The above raised funds were remitted into the 020601-1256340-4 raised funds special account opened by the company in China Merchants Yonglong Bank Co., Ltd. on January 9, 2019, and the initial deposit amount was HK $44805725864 (equivalent to RMB 39169165550). As of December 31, 2021, the unused raised funds have been transferred to other bank accounts of the company and relevant subsidiaries of the company.
(III) funds raised from initial public offering of a shares
With the approval of registration of Shanghai Junshi Biosciences Co.Ltd(688180) initial public offering (zjxk [2020] No. 940) issued by China Securities Regulatory Commission, in July 2020, the company publicly issued 87130000 ordinary shares (A shares) in Shanghai Stock Exchange, with an issue price of 55.50 yuan per share and a total raised capital of 483571500000 yuan, After deducting the issuance expenses excluding tax of RMB 33873667327, the net amount of funds actually raised was RMB 449697832673. The actual amount received is RMB 451566138750, including other outstanding issuance expenses of RMB 1868306077. All the above-mentioned raised funds have been received on July 8, 2020, verified by Rongcheng Certified Public Accountants (special general partnership) and issued the capital verification report (Rongcheng Yan Zi [2020] No. 230z0103).
1. Management system of raised funds
In order to standardize the management and use of the company’s raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the provisions of the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies, the guidelines for the self-discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and other laws, regulations and normative documents, and in combination with the actual situation of the company, The company has formulated the Shanghai Junshi Biosciences Co.Ltd(688180) raised funds management system, which has made clear provisions on the storage, use and supervision of raised funds.
2. Tripartite supervision agreement of raised funds
According to the requirements of the above laws, regulations and normative documents, the company signed the tripartite supervision agreement on the storage of special account for raised funds with the recommendation institution and the commercial bank storing the raised funds, opened a special account for raised funds and stored the raised funds in a special account.
3. Initial deposit of raised funds
All the above raised funds have been received on July 8, 2020, and their initial deposits are as follows:
Monetary unit: RMB
Sequence bank name account name bank account number amount
number
Shanghai Shanghai Junshi Biosciences Co.Ltd(688180)
1 Bank Of Shanghai Co.Ltd(601229) Nanhui sub branch Pharmaceutical Technology Co., Ltd
China China Construction Bank Corporation(601939) Co., Ltd. Shanghai Shanghai Junshi Biosciences Co.Ltd(688180)
2. Shanghai Branch Pharmaceutical Technology Co., Ltd. 31050136360 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 58428000000000 bank business department Co., Ltd
China Merchants Bank Co.Ltd(600036) Shanghai Changle Shanghai Shanghai Junshi Biosciences Co.Ltd(688180)
3 sub branch Pharmaceutical Technology Co., Ltd. 755928673210110208566138750
China Merchants Bank Co.Ltd(600036) Shanghai Free Trade Shanghai Shanghai Junshi Biosciences Co.Ltd(688180)
4 branch business department Pharmaceutical Technology Co., Ltd. 75592867321086685000000000
Total 451566138750
4. Four party supervision agreement on raised funds
On July 24, 2020, the 25th meeting of the second board of directors and the 20th meeting of the second board of supervisors considered and approved the proposal on adding the implementation subject of raised investment projects and signing the Quartet supervision agreement on the storage of raised funds in a special account, and agreed to add wholly-owned subsidiaries Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) Engineering Co., Ltd., Suzhou Zhonghe Biomedical Technology Co., Ltd Suzhou junmeng Biomedical Technology Co., Ltd. is the implementation subject of “innovative drug R & D project” and “repayment of bank loans and supplement of working capital”, and has established a special account for raising funds.
On September 29, 2020, the 27th meeting of the second board of directors and the 22nd Meeting of the second board of supervisors considered and approved the proposal on adding the implementation subject of raised investment projects and signing the Quartet supervision agreement on the storage of raised funds in a special account, and agreed to add Suzhou Shanghai Junshi Biosciences Co.Ltd(688180) Pharmaceutical Technology Co., Ltd., Suzhou junao precision Medicine Co., Ltd Suzhou Shanghai Junshi Biosciences Co.Ltd(688180) Engineering Co., Ltd. is the implementation subject of “repayment of bank loans and supplement of working capital”, and has established a special account for raised funds.
On December 16, 2020, the company held the 31st meeting of the second board of directors and the 25th meeting of the second board of supervisors, deliberated and approved the proposal on adding the implementation subject of the raised investment project and signing the Quartet supervision agreement on the storage of the raised funds in the special account, and agreed to add the wholly-owned subsidiary topalliance Biosciences Inc. as the “innovative drug R & D project” The implementation subject of “repayment of bank loans and supplement of working capital” and set up a special account for raised funds.
5. Storage of raised funds in special account
As of December 31, 2021, the balance of funds raised by the company was 86197507543 yuan. See the following table for details:
Monetary unit: RMB
Project amount
The recorded amount of raised funds is 451566138750
Less: other issuance expenses of raised investment projects 1868306077
Less: Replacement Fund of 84971430534 invested in investment projects with raised funds in advance with self raised funds
Less: 172413366249 yuan of expenditure for raised investment projects
Less: permanent supplementary working capital amount of over raised funds 55268629729
Less: idle raised funds temporarily replenish working capital 54200000000
Plus: net amount of interest income of raised funds deducting handling charges and exchange losses 3353101382
As of December 31, 2021, the balance of raised funds was 86197507543
As of December 31, 2021, the specific deposits of the company’s raised funds are as follows:
Monetary unit: RMB
Sequence bank name account name bank account number currency amount in original currency
number
Bank of Shanghai Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) medical people’s Bank of China
1 Nanhui sub branch Pharmaceutical Technology Co., Ltd. 3190330 Zhejiang Canaan Technology Limited(300412) 049 yuan 2118338484621183384846 company
China Construction
Bank of China Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) medical people’s Bank
2 Pharmaceutical Technology Co., Ltd. 31050136360 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 584 yuan 9516447395164473 Shanghai Branch
Bank business department
China Merchants Bank Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) medical people’s Bank
3 Shanghai Changle Pharmaceutical Technology Co., Ltd. 755928673210110 yuan 39125391989 sub branch 1 company
China Merchants Bank Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) medical
4 Shanghai free trade Pharmaceutical Technology Co., Ltd. 755928673210866 people’s 1518904447615189044476 branch business company currency
Department
China Merchants Bank Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) ICBC
5 Shanghai Chang
